{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:20:13Z","timestamp":1789395613419,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004909","name":"Universidade Federal Do Rio Grande Do Sul","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004909","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Braz J Microbiol"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Proper treatment for infections caused by\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      , particularly methicillin-resistant strains (MRSA), remains a constant challenge in hospital settings. In this context, the search for new antimicrobials, such as delafloxacin, has become necessary. Delafloxacin is a novel quinolone with a broad spectrum of activity against both gram-positive and gram-negative bacteria, offering a new therapeutic option for the treatment of infections caused by multidrug-resistant bacteria.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      117\n                      <jats:italic>S. aureus<\/jats:italic>\n                      isolates were included in this study: 48\n                      <jats:italic>S. aureus<\/jats:italic>\n                      methicillin-susceptible (MSSA) and 69\n                      <jats:italic>S. aureus<\/jats:italic>\n                      methicillin-resistant (MRSA). Isolates were recovered from skin and soft tissue sites, respiratory tract, and blood cultures. Delafloxacin susceptibility was assessed using the gradient diffusion strip (Liofilchem\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ), and the results were interpreted according to the BrCAST guidelines. To assess the clonal profile of\n                      <jats:italic>S. aureus<\/jats:italic>\n                      , Fourier-transform infrared (FTIR) spectroscopy was employed using the IR Biotyper system.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Susceptibility to delafloxacin varied from 97.8% to 54.7% for isolates from skin\/soft tissue and from respiratory tract, respectively. Blood culture isolates exhibited a Minimum Inhibitory Concentration (MIC)\u2009\u2264\u20090.5\u00a0mg\/L. FTIR analysis using the IR Biotyper indicated a diverse distribution among the isolates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      Due to the high sensitivity rates found in this study, delafloxacin may be considered as a good therapeutic option for the treatment of\n                      <jats:italic>S. aureus<\/jats:italic>\n                      infections, including MRSA, particularly in skin and soft tissue infections. The IR Biotyper analysis revealed considerable clonal variation among the isolates, enhancing the robustness of the study.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s42770-026-02084-7","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:40:15Z","timestamp":1789393215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of in vitro activity of delafloxacin against Staphylococcus aureus MSSA and MRSA isolated from a Brazilian tertiary hospital"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0763-1430","authenticated-orcid":false,"given":"Patricia Orlandi","family":"Barth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Ribas","family":"Ucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afonso Lu\u00eds","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"2084_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13017-018-0219-9","volume":"13","author":"M Sartelli","year":"2018","unstructured":"Sartelli M, Guirao X, Hardcastle TC et al (2018) WSES\/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections. World J Emerg Surg 13:58. https:\/\/doi.org\/10.1186\/s13017-018-0219-9","journal-title":"World J Emerg Surg"},{"issue":"Suppl 3","key":"2084_CR2","doi-asserted-by":"publisher","first-page":"S200","DOI":"10.1093\/cid\/ciz003","volume":"68","author":"D Shortridge","year":"2019","unstructured":"Shortridge D, Flamm RK (2019) Comparative in vitro activities of new antibiotics for the treatment of skin infections. Clin Infect Dis 68(Suppl 3):S200\u2013S205. https:\/\/doi.org\/10.1093\/cid\/ciz003","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2084_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/antibiotics8020052","volume":"8","author":"M Gajd\u00e1cs","year":"2019","unstructured":"Gajd\u00e1cs M (2019) The continuing threat of methicillin-resistant Staphylococcus aureus. Antibiot (Basel) 8(2):52. https:\/\/doi.org\/10.3390\/antibiotics8020052","journal-title":"Antibiot (Basel)"},{"issue":"6","key":"2084_CR4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1086\/511872","volume":"44","author":"JJ Ruhe","year":"2007","unstructured":"Ruhe JJ, Smith N, Bradsher RW et al (2007) Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 44(6):777\u2013784. https:\/\/doi.org\/10.1086\/511872","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2084_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000501788","volume":"29","author":"B Kot","year":"2020","unstructured":"Kot B, Wierzchowska K, Piechota M, Gru\u017cewska A (2020) Antimicrobial resistance patterns in methicillin-resistant Staphylococcus aureus from patients hospitalized during 2015\u20132017 in hospitals in Poland. Med Princ Pract 29(1):61\u201368. https:\/\/doi.org\/10.1159\/000501788","journal-title":"Med Princ Pract"},{"key":"2084_CR6","doi-asserted-by":"publisher","first-page":"e20200431","DOI":"10.1590\/0037-8682-0431-2020","volume":"53","author":"AM Rossato","year":"2020","unstructured":"Rossato AM, Primon-Barros M, Rocha LDL, Reiter KC, Dias CAG, d\u2019Azevedo PA (2020) Resistance profile to antimicrobial agents in methicillin-resistant Staphylococcus aureus isolated from hospitals in South Brazil between 2014\u20132019. Rev Soc Bras Med Trop 53:e20200431. https:\/\/doi.org\/10.1590\/0037-8682-0431-2020","journal-title":"Rev Soc Bras Med Trop"},{"issue":"4","key":"2084_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1080\/20009666.2019.1651482","volume":"9","author":"R Tirupathi","year":"2019","unstructured":"Tirupathi R, Areti S, Salim SA, Palabindala V, Jonnalagadda N (2019) Acute bacterial skin and soft tissue infections: new drugs in ID armamentarium. J Community Hosp Intern Med Perspect 9(4):310\u2013313. https:\/\/doi.org\/10.1080\/20009666.2019.1651482","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"11","key":"2084_CR8","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1080\/17425255.2017.1386654","volume":"13","author":"M Basset","year":"2017","unstructured":"Basset M, Pecori D, Cojutti P, Righi E, Pea F (2017) Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections. Expert Opin Drug Metab Toxicol 13(11):1193\u20131200. https:\/\/doi.org\/10.1080\/17425255.2017.1386654","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2084_CR9","unstructured":"Ohshita Y, Yazaki A (1997) In vitro studies with WQ-3034, a newly synthesized acidic fluoroquinolone, abstr. F-164. ; Abstr. 37th Intersci. Conf. Antimicrob. Agents Chemother., Toronto, Canada"},{"issue":"2","key":"2084_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1128\/AAC.01201-10","volume":"55","author":"S Lemaire","year":"2011","unstructured":"Lemaire S, Tulkens PM, Van Bambeke F (2011) Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother 55(2):649\u2013658","journal-title":"Antimicrob Agents Chemother"},{"key":"2084_CR11","unstructured":"BRASIL. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (2020) Resolu\u00e7\u00e3o RE n\u00ba 5.215, de 18 de dezembro de 2020. [Concede o registro do medicamento novo Delabaxi (delafloxacino meglumina) \u00e0 empresa Eurofarma Laborat\u00f3rios S.A.]. Di\u00e1rio Oficial da Uni\u00e3o: se\u00e7\u00e3o 1, Bras\u00edlia, DF, n. 243, p. 112, 21 dez. Available from: in.gov.br. Acecessed on: 13th Aug . 2026"},{"key":"2084_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jgar.2020.09.027","volume":"23","author":"D Shortridge","year":"2020","unstructured":"Shortridge D, Pfaller MA, Streit JM, Flamm RK (2020) Update on the activity of delafloxacin against acute bacterial skin and skin-structure infection isolates from European hospitals (2014\u20132019). J Glob Antimicrob Resist 23:278\u2013283. https:\/\/doi.org\/10.1016\/j.jgar.2020.09.027","journal-title":"J Glob Antimicrob Resist"},{"issue":"9","key":"2084_CR13","doi-asserted-by":"publisher","first-page":"e00772","DOI":"10.1128\/AAC.00772-17","volume":"61","author":"S McCurdy","year":"2017","unstructured":"McCurdy S, Lawrence L, Quintas M et al (2017) In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 61(9):e00772\u2013e00717. https:\/\/doi.org\/10.1128\/AAC.00772-17","journal-title":"Antimicrob Agents Chemother"},{"key":"2084_CR14","unstructured":"Brazilian Committee on Antimicrobial Susceptibility Testing (BrCAST) Tabela de pontos de corte cl\u00ednicos, v.15.0, 2025. . Available from: https:\/\/brcast.org.br\/ Accessed on 17th Dec 2024. https:\/\/brcast.org.br\/"},{"key":"2084_CR15","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2217\/fmb-2020-0276","volume":"16","author":"D Lombardo","year":"2021","unstructured":"Lombardo D, Cordovana M, Deidda F, Pane M, Ambretti S (2021) Application of Fourier transform infrared spectroscopy for real-time typing of an Acinetobacter baumannii outbreak in an intensive care unit. Future Microbiol 16:1239\u20131250. https:\/\/doi.org\/10.2217\/fmb-2020-0276","journal-title":"Future Microbiol"},{"issue":"3","key":"2084_CR16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/8755122519834615","volume":"35","author":"Y Lee","year":"2019","unstructured":"Lee Y, Burton C, Bevel K (2019) Delafloxacin for the treatment of acute bacterial skin and skin structure infections. J Pharm Technol 35(3):110\u2013118. https:\/\/doi.org\/10.1177\/8755122519834615","journal-title":"J Pharm Technol"},{"issue":"5","key":"2084_CR17","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/cid\/ciy165","volume":"67","author":"W O\u2019Riordan","year":"2018","unstructured":"O\u2019Riordan W, McManus A, Teras J et al (2018) A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections. Clin Infect Dis 67(5):657\u2013666. https:\/\/doi.org\/10.1093\/cid\/ciy165","journal-title":"Clin Infect Dis"},{"key":"2084_CR18","unstructured":"Food and Drug Administration (2017) FDA approves Baxdela to treat acute bacterial skin and skin structure infections (ABSSSI). [Accessed August 13, 2026]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208610Orig1s000,208611Orig1s000SumR.pdf"},{"key":"2084_CR19","volume-title":"Quofenix (delafloxacin): EPAR \u2013 Product information","author":"European Medicines Agency","year":"2025","unstructured":"European Medicines Agency (2025) Quofenix (delafloxacin): EPAR \u2013 Product information. EMA, Amsterdam"},{"issue":"2","key":"2084_CR20","doi-asserted-by":"publisher","first-page":"dlad034","DOI":"10.1093\/jacamr\/dlad034","volume":"5","author":"B Gerges","year":"2023","unstructured":"Gerges B, Rolston K, Shelburne SA, Rosenblatt J, Prince R, Raad I (2023) In vitro activity of delafloxacin and comparator agents against bacterial pathogens isolated from patients with cancer. JAC Antimicrob Resist 5(2):dlad034. https:\/\/doi.org\/10.1093\/jacamr\/dlad034","journal-title":"JAC Antimicrob Resist"},{"issue":"2","key":"2084_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ram.2021.02.012","volume":"54","author":"F Nicola","year":"2022","unstructured":"Nicola F, Azula N, Santoni G, Smayevsky J (2022) Actividad in vitro de delafloxacina frente a microorganismos aislados de infecciones osteoarticulares y de piel y partes blandas en Buenos Aires, Argentina. Rev Argent Microbiol 54(2):114\u2013119. https:\/\/doi.org\/10.1016\/j.ram.2021.02.012","journal-title":"Rev Argent Microbiol"},{"issue":"1","key":"2084_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12348-020-0200-0","volume":"10","author":"KC Fan","year":"2020","unstructured":"Fan KC, Lin J, Yannuzzi NA et al (2020) In vitro susceptibilities of methicillin-susceptible and resistant staphylococci to traditional antibiotics compared to a novel fluoroquinolone. J Ophthalmic Inflamm Infect 10(1):9. https:\/\/doi.org\/10.1186\/s12348-020-0200-0","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"14","key":"2084_CR23","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s40265-020-01407-8","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ (2020) Delafloxacin: a review in acute bacterial skin and skin structure infections. Drugs 80(14):1507\u20131518. https:\/\/doi.org\/10.1007\/s40265-020-01407-8","journal-title":"Drugs"},{"issue":"6","key":"2084_CR24","doi-asserted-by":"publisher","first-page":"103867","DOI":"10.1016\/j.bjid.2024.103867","volume":"28","author":"\u00c1CDS Ribeiro","year":"2024","unstructured":"Ribeiro \u00c1CDS, Santos FF, Valiatti TB et al (2024) Comparative in vitro activity of delafloxacin and other antimicrobials against isolates from patients with acute bacterial skin, skin-structure infection and osteomyelitis. Braz J Infect Dis 28(6):103867. https:\/\/doi.org\/10.1016\/j.bjid.2024.103867","journal-title":"Braz J Infect Dis"}],"container-title":["Brazilian Journal of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42770-026-02084-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42770-026-02084-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42770-026-02084-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:40:19Z","timestamp":1789393219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42770-026-02084-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["2084"],"URL":"https:\/\/doi.org\/10.1007\/s42770-026-02084-7","relation":{},"ISSN":["1517-8382","1678-4405"],"issn-type":[{"value":"1517-8382","type":"print"},{"value":"1678-4405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work the author(s) used ChatGPT in order to improve the text. After using this tool, the authors reviewed and edited the content as needed and takes full responsibility for the content of the published article.","order":2,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the manuscript preparation process","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"270"}}